ADMA BIOLOGICS Reports $141.1 Million Quarterly Revenue
ADMA BIOLOGICS reported quarterly results highlighted by 3Q 2026 Total Revenue of $141.1 Million, Increasing 5% Year-over-Year, according to its earnings release filed with an 8-K Wednesday.
3Q 2026 ASCENIV Revenue of $124.7 Million, Increasing 31% Year-over-Year. 3Q 2026 GAAP Net Income of $49.9 Million, Increasing 37% Year-over-Year. 3Q 2026 Adjusted Net Income (1) of $51.1 Million, Increasing 31% Year-over-Year. 3Q 2026 GAAP Basic EPS of $0.22, Increasing 47% Year-over-Year.
Adam Grossman said, "Our third quarter results demonstrate ADMA’s ability to translate accelerating ASCENIV demand into substantial earnings growth,"
Results detail
Further figures in the release included 3Q 2026 Adjusted Basic EPS (2) of $0.23, Increasing 44% Year-over-Year; 3Q 2026 Adjusted EBITDA (3) of $77.3 Million, Increasing 32% Year-over-Year; FY2026 total revenue expected to be at least $530 million; FY2026 Adjusted Net Income expected to be at least $180 million.
The filing is an Item 2.02 results announcement furnished with Exhibit 99.1. Comparisons use the year-earlier period as presented by ADMA BIOLOGICS unless the release specifies another baseline. Where both GAAP and non-GAAP metrics appear, both are summarized when the extract includes them.
Segment mix, cash flow and any outlook language in the release are the usual secondary reads after the headline revenue and earnings figures. One-time items—restructuring, impairments, gains on sales or legal settlements—can move GAAP profit without changing the run-rate story, so reconciliations remain essential.
Why it matters
For retail investors, the ADMA BIOLOGICS print is a check on whether growth, margins and cash generation are moving together. The figures above come from the company’s Exhibit 99.1 earnings materials; how they stack up against the prior-year run rate and any guide published with the release will shape the near-term debate.
By the numbers
- 3Q 2026 Total Revenue of $141.1 Million, Increasing 5% Year-over-Year
- 3Q 2026 ASCENIV Revenue of $124.7 Million, Increasing 31% Year-over-Year
- 3Q 2026 GAAP Net Income of $49.9 Million, Increasing 37% Year-over-Year
- 3Q 2026 Adjusted Net Income (1) of $51.1 Million, Increasing 31% Year-over-Year
- 3Q 2026 GAAP Basic EPS of $0.22, Increasing 47% Year-over-Year
- 3Q 2026 Adjusted Basic EPS (2) of $0.23, Increasing 44% Year-over-Year
Sources
- ADMA BIOLOGICS, INC. Form 8-K with quarterly financial results, filed 2026-11-04 (accession 0001140361-26-041959)
This article is for informational and educational purposes only and is not investment advice. It is not a recommendation to buy or sell any security.
Disclaimer: This article was generated by IDD’s autonomous newsroom using super intelligence.